Stay updated on FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial

Sign up to get notified when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A new Locations section now lists Santa Monica, California as a study site. The old California Locations block and the HHS Vulnerability Disclosure link were removed, and the revision tag updated to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T08:57:46.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.1 to v3.3.2 in the page footer.
    Difference
    0.1%
    Check dated 2025-12-01T16:31:26.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The page footer now shows Revision: v3.3.1 instead of v3.2.0. This change does not affect the study details or any information presented on the page.
    Difference
    0.1%
    Check dated 2025-11-24T11:17:05.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    Removed a government funding/operating status notice from the bottom of the page; no trial data, enrollment details, or navigation elements were altered. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T06:14:09.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    No notable changes detected; the page content and layout appear unchanged.
    Difference
    0.4%
    Check dated 2025-11-03T00:47:29.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    Key updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If there are no other changes, this is the main shift.
    Difference
    3%
    Check dated 2025-10-05T07:13:04.000Z thumbnail image

Stay in the know with updates to FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.